Kenneth C. Anderson, MD

Kraft Family Professor of Medicine
Harvard Medical School
Chief, Division of Hematologic Neoplasia
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Kenneth Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as chief of the Division of Hematologic Neoplasia, director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute. 

Dr. Anderson serves as chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee; as a Cancer and Leukemia Group B Principal Investigator; on the Board of Scientific Advisors of the International Myeloma Foundation; on the Board of Directors and Chair of both the Scientific Advisory Board of the Multiple Myeloma Research Foundation and the Steering Committee of the Multiple Myeloma Research Consortium. Dr. Anderson has published more than 350 original articles, 250 chapters, has edited multiple textbooks on both multiple myeloma and on transfusion medicine, and was named editor in chief of Clinical Cancer Research. In addition, he is a Doris Duke Distinguished Clinical Research Scientist and has received numerous other awards.

Over the last two decades, Dr. Anderson has focused his translational research studies on B cell malignancies, especially multiple myeloma. His team led both preclinical and clinical trials of the novel proteasome inhibitor bortezomib, as well as lenalidomide. His research offers great promise to improve patient outcome in hematologic malignancies and solid tumors.

Faculty Disclosure
Dr. Kenneth Anderson has received consultant fees from Celgene Corporation, Millennium Pharmaceuticals, Inc., and Novartis AG, as well as grant support related to research activities from Celgene and Millennium.

Last modified: February 21, 2013